imugene

Scientists dosed the first patient this week in a small clinical trial of an experimental cancer treatment — one that relies on a novel kind of ally. The treatment uses a virus engineered to selectively kill cancer cells, while also amplifying the body’s immune response to the cancer. The hope is that this therapy can…